论文部分内容阅读
目的检测上皮性卵巢癌组织中WT1与CA125蛋白的表达,探讨其临床意义。方法采用免疫组织化学SP方法检测WT1与CA125蛋白在40例恶性卵巢上皮性肿瘤(上皮性卵巢癌)、20例交界性卵巢上皮性肿瘤、20例良性卵巢上皮性肿瘤和10例正常卵巢组织中的表达。结果上皮性卵巢癌组织中WT1和CA125的阳性表达率分别为57.5%和70%,显著高于卵巢交界性肿瘤、卵巢良性肿瘤和正常卵巢组织(P<0.05);上皮性卵巢癌组织中WT1和CA125的表达呈正相关(P<0.05)。结论 WT1可能与上皮性卵巢癌发生有关,可能成为卵巢上皮性肿瘤诊断的客观辅助指标。
Objective To detect the expression of WT1 and CA125 protein in epithelial ovarian cancer and to explore its clinical significance. Methods Immunohistochemical SP method was used to detect the expression of WT1 and CA125 proteins in 40 cases of malignant epithelial ovarian cancer (epithelial ovarian cancer), 20 cases of borderline ovarian epithelial tumor, 20 cases of benign ovarian epithelial tumor and 10 cases of normal ovarian tissue expression. Results The positive rates of WT1 and CA125 in epithelial ovarian cancer were 57.5% and 70%, respectively, which were significantly higher than those in borderline ovarian tumors, benign ovarian tumors and normal ovarian tissues (P <0.05) And CA125 expression was positively correlated (P <0.05). Conclusion WT1 may be related to the occurrence of epithelial ovarian cancer and may be an objective auxiliary indicator for the diagnosis of epithelial ovarian cancer.